<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717288</url>
  </required_header>
  <id_info>
    <org_study_id>2007H0210</org_study_id>
    <secondary_id>60016576</secondary_id>
    <nct_id>NCT00717288</nct_id>
  </id_info>
  <brief_title>Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir</brief_title>
  <official_title>Transitioning Post-cardiothoracic Surgery Patients From Intravenous Insulin to the Subcutaneous Route With Insulin Detemir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we will determine the proper method for transitioning patients from a
      continuous insulin infusion to periodic injections of a newer long-acting insulin called
      detemir (Levemir).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High sugar (glucose) is common after surgery, even in patients who do not have diabetes. High
      glucose contributes to severe hospital complications and even death. Insulin infusions appear
      to reduce this risk, but are generally only continued for a few days after surgery. In this
      study, we will determine the proper method for transitioning patients from a continuous
      insulin infusion to periodic injections of a newer long-acting insulin called detemir
      (Levemir). 90 patients who have undergone recent open heart surgery and are requiring an
      insulin infusion will be enrolled. They will be randomly assigned to one of three doses of
      detemir, which consists of 50%, 65%, or 80% of the total daily insulin infusion requirement
      in the fasting state. Subjects will also receive identical mealtime coverage according to the
      amount of carbohydrate (glucose) that is ingested. It is expected that the high dose group
      will achieve superior glycemic control without excessive hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3</measure>
    <time_frame>day 2, day 3</time_frame>
    <description>Number of patients with a morning glucose between 80-130 mg/dl on day 2 and day 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With Hypoglycemia (Defined as Glucose &lt;65 mg/dl)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of patients with hypoglycemia (defined as glucose &lt;65 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversion to Intravenous Insulin for Failure of Glycemic Control</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of participants who went back on intravenous insulin for failure of glycemic control.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Detemir dosed at 50% of calculated basal insulin infusion requirements</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Detemir dosed at 65% of calculated basal insulin infusion requirements</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Detemir dosed at 80% of calculated basal insulin infusion requirements</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes mellitus

          -  post-cardiothoracic surgery

          -  requiring an insulin infusion of at least 1 unit/hour

          -  Age 18-75

        Exclusion Criteria:

          -  Glucocorticoids

          -  total parenteral nutrition (TPN) or tube feeds

          -  Pregnancy

          -  Surgical procedures in the next 48 hours for whom intravenous (IV) insulin will be
             expected

          -  Expected length of stay less than 48 hours following cessation of the insulin drip

          -  Patients using subcutaneous insulin pumps

          -  Diabetic ketoacidosis

          -  End-stage renal disease

          -  End-stage liver disease

          -  Coma

          -  Potentially sensitive admissions: prisoners, human immunodeficiency virus(HIV),
             suicidality

          -  Unable to give consent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Dungan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>August 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2011</results_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kathleen Dungan</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>open heart surgery</keyword>
  <keyword>cardiothoracic surgery</keyword>
  <keyword>detemir</keyword>
  <keyword>insulin infusion</keyword>
  <keyword>intravenous insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50% Conversion Factor</title>
          <description>Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="P2">
          <title>65% Conversion Factor</title>
          <description>Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="P3">
          <title>80% Conversion Factor</title>
          <description>Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50% Conversion Factor</title>
          <description>Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="B2">
          <title>65% Conversion Factor</title>
          <description>Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="B3">
          <title>80% Conversion Factor</title>
          <description>Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8.0"/>
                    <measurement group_id="B2" value="57" spread="9.1"/>
                    <measurement group_id="B3" value="61" spread="7.6"/>
                    <measurement group_id="B4" value="58.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3</title>
        <description>Number of patients with a morning glucose between 80-130 mg/dl on day 2 and day 3</description>
        <time_frame>day 2, day 3</time_frame>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>50% Conversion Factor</title>
            <description>Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily</description>
          </group>
          <group group_id="O2">
            <title>65% Conversion Factor</title>
            <description>Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily</description>
          </group>
          <group group_id="O3">
            <title>80% Conversion Factor</title>
            <description>Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3</title>
          <description>Number of patients with a morning glucose between 80-130 mg/dl on day 2 and day 3</description>
          <population>intention to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Hypoglycemia (Defined as Glucose &lt;65 mg/dl)</title>
        <description>Number of patients with hypoglycemia (defined as glucose &lt;65 mg/dl)</description>
        <time_frame>48 hours</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>50% Conversion Factor</title>
            <description>Number of subjects with a BG value &lt;65 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>65% Conversion Factor</title>
            <description>Number of subjects with a BG value &lt;65 mg/dl</description>
          </group>
          <group group_id="O3">
            <title>80% Conversion Factor</title>
            <description>Number of subjects with a BG value &lt;65 mg/dl</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Hypoglycemia (Defined as Glucose &lt;65 mg/dl)</title>
          <description>Number of patients with hypoglycemia (defined as glucose &lt;65 mg/dl)</description>
          <population>Intention to treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reversion to Intravenous Insulin for Failure of Glycemic Control</title>
        <description>Number of participants who went back on intravenous insulin for failure of glycemic control.</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50% Conversion Factor</title>
            <description>Number of subjects that reverted back to an insulin drip</description>
          </group>
          <group group_id="O2">
            <title>65% Conversion Factor</title>
            <description>Number of subjects that reverted back to an insulin drip</description>
          </group>
          <group group_id="O3">
            <title>80% Conversion Factor</title>
            <description>Number of subjects that reverted back to an insulin drip</description>
          </group>
        </group_list>
        <measure>
          <title>Reversion to Intravenous Insulin for Failure of Glycemic Control</title>
          <description>Number of participants who went back on intravenous insulin for failure of glycemic control.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>50% Conversion Factor</title>
          <description>Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="E2">
          <title>65% Conversion Factor</title>
          <description>Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
        <group group_id="E3">
          <title>80% Conversion Factor</title>
          <description>Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BG &lt;40 mg/dl</sub_title>
                <description>Any BG &lt;40 mg/dl</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Dungan, MD</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-292-3800</phone>
      <email>kathleen.dungan@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

